Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients

Metabolism: Clinical and Experimental

Volumn 50, Issue 10, 2001, Pages 1147-1151

  Haenni, Arvo ^a   Öhrvall, Margareta ^a   Lithell, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; GLUCOSE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; METFORMIN; PLACEBO; SIMVASTATIN; SULFONYLUREA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG INHIBITION; DYSLIPOPROTEINEMIA; FEMALE; FRACTIONATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERLIPOPROTEINEMIA; INSULIN SENSITIVITY; LIPOPROTEIN METABOLISM; MAGNESIUM BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0034764725     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.26755     Document Type: Article

References (37)

1. Epidemiological studies on the relationship between magnesium intake and cardiovascular diseases
2. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: The ARIC study. Atherosclerosis Risk in Communities Study
3. Magnesium, lipids and vascular diseases
4. Oxidative modification of triglyceride-rich lipoproteins in hypertriglyceridemic rats following magnesium deficiency
5. Effect of dietary protein and magnesium on plasma cholesterol in weanling rats
6. Effect of dietary protein and magnesium on plasma triglycerides in weanling rats
7. Combined effects of magnesium deficiency and the atherogenic level of low density lipoprotein on uptake and metabolism of low density lipoprotein by cultured human endothelial cells
8. Atherogenic lipid fractions are related to ionized magnesium status
9. Effect of dietary magnesium on development of atherosclerosis in cholesterol-fed rabbits
10. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study
11. Effects of magnesium treatment on hyperlipidemia
12. Effects of magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus
13. New data about the effects of oral physiological magnesium supplementation on several cardiovascular risk factors (lipids and blood pressure)
14. The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance
15. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S)
17. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
18. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
20. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
21. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
22. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension
23. On the intravenous glucose tolerance test
24. Glucose clamp technique: A method for quantifying insulin secretion and resistance
25. The 2 × 2 cross-over trial with continuous data
26. Effects of HMG-CoA reductase inhibitors on erythrocyte magnesium levels
27. Dietary fat and blood pressure: An intervention study on the effects of a low-fat diet with two levels of polyunsaturated fat
28. Renal hypomagnesemia in human diabetes mellitus: Its relation to glucose homeostasis
29. Magnesium deficiency in IDDM related to level of glycosylated hemoglobin
30. Serum ionized magnesium levels in type 2 diabetic patients with microalbuminuria or clinical proteinuria
31. Hyperglycaemia without glucosuria increases renal magnesium excretion
32. Influence of various nutrients on urinary divalent cation excretion
33. Insulin increases renal magnesium excretion: A possible cause of magnesium depletion in hyperinsulinemic states
34. Impaired insulin-induced erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in type 2 (non-insulin-dependent) diabetic patients
35. Cellular ions in hypertension, diabetes, and obesity